Phase 1 Neuroendocrine Tumor Clinical Trials
28 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 28 trials
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 1
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Neuroendocrine TumorsNeuroendocrine Carcinoma
Peter Hosein, MD36 enrolled1 locationNCT06889493
Recruiting
Phase 1
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 1
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Pancreatic NeoplasmMetastatic Pancreatic Neuroendocrine TumorStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more
National Cancer Institute (NCI)24 enrolled10 locationsNCT05687123
Recruiting
Phase 1Phase 2
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Hepatocellular CarcinomaNeuroendocrine TumorsGastrointestinal Cancer Metastatic
Teclison Ltd.25 enrolled2 locationsNCT02174549
Recruiting
Phase 1Phase 2
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors
National Cancer Institute (NCI)56 enrolled1 locationNCT04086485
Recruiting
Phase 1Phase 2
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Neuroendocrine Tumors,Gastroenteropancreatic
National Health Research Institutes, Taiwan49 enrolled11 locationsNCT05048901
Recruiting
Phase 1
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Neuroendocrine TumorsCarcinoma, NeuroendocrineNeuroendocrine Carcinomas+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06041516
Recruiting
Phase 1
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Neuroendocrine TumorsSomatostatin Receptor-positive Neuroendocrine Tumor
University of Wisconsin, Madison10 enrolled1 locationNCT06122610
Recruiting
Phase 1
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1Phase 2
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Neuroendocrine NeoplasmNeuroendocrine TumorsSST2-positive Neuroendocrine Neoplasms
Crinetics Pharmaceuticals Inc.150 enrolled21 locationsNCT07129252
Recruiting
Phase 1
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Digestive System Neuroendocrine TumorUnresectable Digestive System Neuroendocrine NeoplasmUnresectable Digestive System Neuroendocrine Tumor G1+1 more
Emory University15 enrolled2 locationsNCT07150546
Recruiting
Phase 1Phase 2
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Neuroendocrine Tumors
Chimeric Therapeutics135 enrolled4 locationsNCT06055439
Recruiting
Phase 1
F-Tryptophan PET/CT in Human Cancers
Breast CancerRectal CancerNeuroendocrine Tumors+2 more
Barbara Ann Karmanos Cancer Institute24 enrolled1 locationNCT05556473
Recruiting
Phase 1
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Breast Cancer MetastaticNeuroendocrine TumorsRenal Cell Carcinoma (RCC)+2 more
SAPU NANO (US) LLC27 enrolled1 locationNCT07369505
Recruiting
Phase 1
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Metastatic Pancreatic Neuroendocrine Tumor
University of Chicago25 enrolled1 locationNCT06663072
Recruiting
Phase 1Phase 2
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521
Recruiting
Phase 1
Lutathera and ASTX727 in Neuroendocrine Tumours
Neuroendocrine Tumors
Imperial College London27 enrolled1 locationNCT05178693
Recruiting
Phase 1
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Neuroendocrine TumorsSmall Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.22 enrolled1 locationNCT06505824